Immunicum receives 3 500 000 SEK from "The Swedish Governmental Agency for Innovation Systems'" (VINNOVA's) program "Innovations for Future Health" for initiating a clinical phase 1/2-trial on renal cancer patients. Among a total of 250 applicants, Immunicum was one of 13 organizations which received funding, after having been reviewed by 17 experts in different areas, based on the following motivation:

"The application describes an interesting and important project with possibilities of hindering growth and development of existing tumors, and a vision of hindering growth of new tumors. The concept is considered to be based on well-founded research. There is good potential that the treatment will be used as a cancer therapy, as well as for other indications. The application has a good clinical relevance, patent strategy, and commercialization plan."

Immunicum welcomes renowned professor Rolf Kiessling as member of the company's Scientific Advisory Board!

Rolf Kiessling, MD, PhD, is professor in Experimental Oncology at Karolinska Institutet since 1995 and has a part-time position as Chief Physician at Radiumhemmet, Karolinska hospital. His research group is located at the Cancer Center Karolinska (CCK). R.K. has published more than 200 publications in peer review journals and has a broad scientific expertise the field of experimental and clinical immunology. Among his earliest achievements, he discovered and named the Natural Killer cell (NK cell) during the mid 70th, a discovery for which he was awarded "Anders Jahres medicinska pris for yngre forskare" 1985 and "Erik Fehrnströms pris” 1989. A more recent research focus his group has been the area of immune therapy of cancer where his group is carrying out investigator initiated clinical trials on cancer patients and also performing basic research in pre-clinical animal models.